Case File
efta-efta01461014DOJ Data Set 10CorrespondenceEFTA Document EFTA01461014
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01461014
Pages
0
Persons
0
Integrity
Loading PDF viewer...
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
To: Todd Stevens
Subject: FW: Jeffrey Epstein/Southern Financial LLC - Rep Risk Approval [C]
Todd - please see below from Jan Ford/Wayne Salit on the reputational risk committee's assessment of this client
situation early last year. Jeffrey Epstein's CFO (Rich Kahn) has requested the opening of a new account on Tuesday
(email attached). Per the determination made by the committee (below), this would require the account opening to be
brought to reputational risk committee for approval. Please advise us on how to proceed. Thank you, Daniel
From: Wayne Salit
Sent: Monday, March 30, 2015 12:38 PM
To: Daniel Sabba
Subject: Jeffrey Epstein/Southern Financial LLC - Rep Risk Approval [C]
Classification: Confidential
Dan —
Here is the e-mail (dated 2/6/2015 from Jan Ford you requested (see below).
This e-mail is confidential and must not be shared with any third party (including the client) or anyone internally -
other than your direct management chain (e.g. Caroline, etc.) as required.
Please let me know if you require any additional information.
Kind Regards,
Wayne Salit
From: Jan Ford
Sent: Friday, February 06, 2015 8:16 AM
To: Stuart Clarke; Carol Saracco
Cc: Jan Bornebusch; Wayne Salit
Subject: RE: Jeff Epstein [I]
Classification: For Internal use only
Hi Stuart and Carol,
As you know, we agreed last week at RRC to continue business as usual with Jeff Epstein based upon Chip Packard's due
diligence visit with him. I want to make sure the minutes for the RRC meeting accurately reflect what we agreed, so I
asked AML to help re-construct the direction we had given the business. Subject to everyone's agreement, I believe the
guidance was, and should continue to be, as follows (but anyone can jump in to correct this):
1.
The client may continue to conduct trades and transactions in existing accounts without Compliance pre-
approval, provided that the business has determined these transactions do not involve any unusual and/or suspicious
activity or are in a size that is unusually significant or a novel structure.
2.
Consistent with this, CB&S may also "open" accounts to facilitate activity as a booking matter where the activity
has already been approved in AWM.
3.
In addition, the business will need to monitor for any further developments in connection with the reputational
risk of this client relationship and to review transaction/activity conducted in the accounts for any activity, size or
structure as described in #1 above.
Many thanks, Jan
CONFIDENTIAL — PURSUANT TO FED. R. GRIM. P. 6(e)
DB-SDNY-0 122801
CONFIDENTIAL
SDNY_GM_00268985
EFTA01461014
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.